President Donald Trump recently announced that a decision on whether he will follow the Biden Administration’s recommendation to move marijuana from Schedule I to Schedule III was imminent.
But what would Trump actually moving ahead with rescheduling mean?
Moving marijuana to Schedule III would not legalize marijuana nationwide; it would not make it available for prescription, either. Instead, it would give illegal marijuana companies a tax break.
Despite the claim of advocates that such a shift will expand medical research and generate tax revenue, rescheduling would create new problems, weaken existing safeguards, and increase the burden on communities.
Understanding the Current Classification
The federal government categorizes drugs that have addiction potential into legal categories, or schedules based on potential for abuse and accepted medical use. Drug schedules are legal categories and do not indicate harm or overdose potential, meaning drugs in schedule I are not more harmful than drugs in a lower schedule. Schedule I drugs are considered to have a high potential for abuse and no accepted medical use.
Marijuana is currently classified by the federal government as a schedule I drug. That means it meets the criteria for that drug category based on its lack of currently accepted medical use (marijuana itself is not a medication approved by the FDA that could be dispensed at a pharmacy) and high abuse potential with an addiction rate of 30%. Despite marijuana’s lack of medical use, moving marijuana to Schedule III would place it in the same group as substances like anabolic steroids, which have lower abuse potential but recognized medical uses.
This reclassification is not a minor bureaucratic change—it’s a fundamental shift in how the law treats marijuana. It would signal to the public that marijuana is relatively safe and medically beneficial, despite mounting evidence of its health and social harms.
Public Health Implications
Rescheduling would send the wrong message that marijuana use carries minimal risks, but nothing could be further from the truth. This perception shift would lead to higher rates of use, especially among young people, whose brains are still developing. Multiple studies have linked early and frequent marijuana use to impaired cognitive development, lost IQ points, increased risk of psychosis, worse mental health outcomes, and higher likelihood of addiction. Under Schedule I, the legal framework reflects these risks; under Schedule III, that cautionary stance would largely vanish.
The current Schedule I status limits aggressive commercialization. Moving to Schedule III would open the door to large-scale marketing by corporate interests, much like what occurred with alcohol, tobacco, vaping, and online sports betting. History shows that when profit-driven industries take the wheel, public health takes a back seat.
It would also, thanks to so-called state trigger laws, unleash a cascade of state-level reschedulings. “State trigger” laws mean that if the federal government makes this regulatory move, any state with such a law on the books will automatically follow suit. A majority of US states have such laws.
Increased Burden on Law Enforcement and Communities
If marijuana is reclassified to Schedule III, its production and distribution could expand rapidly, including in forms that are more potent and appealing to minors—such as candy-like edibles, concentrates, and flavored vape cartridges. Law enforcement agencies would face a new wave of challenges, from tracking unregulated products to combating impaired driving.
Communities already struggling with drug-related crime could see an uptick in incidents linked to marijuana. States that have loosened marijuana laws have reported increases in crime, traffic fatalities involving THC, and workplace accidents. Poison control is already inundated with THC-related calls and THC poisoning of young children is a daily fixture in emergency departments in legal states.
National Security and International Criminal Links
News investigations have revealed that Chinese and Mexican drug cartels are deeply involved in the U.S. marijuana black market—especially in states where the drug is legal. These cartels use marijuana profits to fund trafficking of fentanyl, methamphetamine, and other deadly substances.
At the same time, law enforcement agencies have documented cases where entities linked to the Chinese Communist Party have financed or operated state-legal marijuana grows on U.S. soil. State legal markets are already fueling crime and failing to regulate bad actors. Rescheduling to Schedule III would lower penalties for traffickers—giving fewer resources to law enforcement—and create cover for these criminal networks to expand operations under the guise of legitimacy, undermining both public safety and national security.
The Research Myth
One of the most repeated arguments for moving marijuana from Schedule I to Schedule III is that it will facilitate medical research. While it’s true that Schedule I substances face tighter controls, researchers can and do obtain approvals to study them. Schedule III research is still heavily regulated and controlled.
The real barrier to research is not classification—it’s the lack of standardized, FDA-approved marijuana products and the variability in plant-based compounds. Rescheduling would not magically resolve these scientific limitations, but it would likely be used as a marketing tool to claim “proven medical benefits” before adequate evidence exists.
Marijuana research can be made more accessible without rescheduling. The Medical Marijuana and Cannabidiol Research Expansion Act is proof of that. Passed in 2022, this bill made researching marijuana easier.
Tax and Industry Expansion Concerns
Section 280E of the federal tax code prohibits companies from writing off activity surrounding Schedule I and II drugs. Moving marijuana to Schedule III would remove this restriction, allowing the industry to expand aggressively. With marijuana in Schedule III, suddenly multibillion dollar conglomerates can write off all expenses related to things like advertising.
This would create a powerful financial incentive for large corporations to target vulnerable populations, repeating patterns seen in alcohol and tobacco marketing. Money is fungible and a $2 billion industry tax break would mean more money for the development of more addictive products, more advertisements plastered everywhere, and more lobbying.
Conclusion: Keep Marijuana in Schedule I
However the idea of rescheduling marijuana to Schedule III sounds, the reality is far more troubling. The Schedule I classification reflects the drug’s high potential for abuse, significant public health risks, and unresolved questions about safety. Downgrading its legal status would undermine decades of public health policy, open the floodgates for commercialization, and increase social, health, and security costs.
The prudent course is to maintain marijuana’s Schedule I status while continuing controlled, scientifically rigorous research—without sending a misleading signal that marijuana is safe or risk-free. Science, public health, and national security, not industry profit, should guide our national drug policy.
This post was created with the assistance of generative AI.